Lennard, L., Cartwright, C., Wade, R., Richards, S., Mitchell, C., Kinsey, S., Eden, T., Lilleyman, J., & Vora, A. (2016). The thiopurine methyltransferase TPMT *1/*3A genotype is associated with a better treatment outcome in the UK ALL97 trial for childhood acute lymphoblastic leukaemia; TPMT heterozygosity is not associated with secondary cancers. 70(2), 298–299.

Lennard, L., et al. The Thiopurine Methyltransferase TPMT *1/*3A Genotype Is Associated with a Better Treatment Outcome in the UK ALL97 Trial for Childhood Acute Lymphoblastic Leukaemia; TPMT Heterozygosity Is Not Associated with Secondary Cancers. no. 2, 2016, pp. 298–99.

Lennard, L, C Cartwright, R Wade, S Richards, C Mitchell, S Kinsey, T Eden, J Lilleyman, and A Vora. 2016. “The Thiopurine Methyltransferase TPMT *1/*3A Genotype Is Associated with a Better Treatment Outcome in the UK ALL97 Trial for Childhood Acute Lymphoblastic Leukaemia; TPMT Heterozygosity Is Not Associated with Secondary Cancers.” In , 70:298–99.